nivolumab,cabozantinib, 177Lu girentuximab
heidelberg pharmaceuticals,esteve,prometheus,bms
['cabo ', 'nivo', 'girentuximab', 'rcc,(-irccs),(-srcc),(-urcc)']
tip: ph 1b/2 study of 177lu girentuximab + cabo + nivo in rx-na ve pts w/ adv ccrcc #asco23 target: n=100 177lu-girentuximab 1480 mbq/m2 every 12 wks for up to 3 rx cycles after 1st cycle, nivo + cabo added prim ep: safety, cr by recist 1.1 
Uro Onc @GACancerCenter | Assoc Prof, Resident PD, and Ronald W. Lewis, MD Chair of Uro Educ @mcg_urology | #mentalhealth research | @urotoday Contributor